Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular ...
The company’s goal is to deliver transformative therapies for patients who have few or no effective treatment options. Astellas’ lead product candidate, AT132, is designed to treat X-linked Myotubular ...
There has been a fourth patient fatality in Astellas' clinical trial of its AT132 gene therapy for the rare disease X-linked myotubular myopathy (XLMTM), which has been halted twice due to safety ...